These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 7912084)

  • 1. Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.
    Molina JM; Ferchal F; Chevret S; Barateau V; Poirot C; Morinet F; Modai J
    AIDS; 1994 Jan; 8(1):27-33. PubMed ID: 7912084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared.
    Kappes JC; Saag MS; Shaw GM; Hahn BH; Chopra P; Chen S; Emini EA; McFarland R; Yang LC; Piatak M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):139-49. PubMed ID: 7552477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term evaluation of zidovudine-treated patients: decrease in plasma and cellular viraemia titres.
    Tamalet C; Masquelier B; Ferchal F; Agut H; Puel J; Brun-Vézinet F; Fleury H; Rouzioux C
    AIDS; 1992 Nov; 6(11):1403-4. PubMed ID: 1361750
    [No Abstract]   [Full Text] [Related]  

  • 4. Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction.
    Edlin BR; Weinstein RA; Whaling SM; Ou CY; Connolly PJ; Moore JL; Bitran JD
    J Infect Dis; 1992 May; 165(5):793-8. PubMed ID: 1349031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction.
    Piatak M; Saag MS; Yang LC; Clark SJ; Kappes JC; Luk KC; Hahn BH; Shaw GM; Lifson JD
    AIDS; 1993 Nov; 7 Suppl 2():S65-71. PubMed ID: 7909227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunological correlates of immune-complex-dissociated HIV-1 p24 antigen in HIV-1-infected children.
    Duiculescu DC; Geffin RB; Scott GB; Scott WA
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):807-15. PubMed ID: 7912730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between surrogate markers, viral load, and disease progression in HIV-1 infection.
    Lafeuillade A; Tamalet C; Pellegrino P; de Micco P; Vignoli C; Quilichini R
    J Acquir Immune Defic Syndr (1988); 1994 Oct; 7(10):1028-33. PubMed ID: 7916049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
    Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
    An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.
    Merigan TC; Hirsch RL; Fisher AC; Meyerson LA; Goldstein G; Winters MA
    AIDS; 1996 Feb; 10(2):159-65. PubMed ID: 8838703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.
    Jurriaans S; Weverling GJ; Goudsmit J; Boogaard J; Brok M; Van Strijp D; Lange J; Koot M; Van Gemen B
    AIDS Res Hum Retroviruses; 1995 Apr; 11(4):473-9. PubMed ID: 7632462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
    BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy.
    Siller L; Martin NL; Kostuchenko P; Beckett L; Rautonen J; Cheng SC; Wara DW
    AIDS; 1993 Mar; 7(3):369-73. PubMed ID: 8097095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery.
    Boyer PJ; Dillon M; Navaie M; Deveikis A; Keller M; O'Rourke S; Bryson YJ
    JAMA; 1994 Jun 22-29; 271(24):1925-30. PubMed ID: 7911164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
    Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
    AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.
    Fiscus SA; Hughes MD; Lathey JL; Pi T; Jackson B; Rasheed S; Elbeik T; Reichman R; Japour A; Byington R; Scott W; Griffith BP; Katzenstein DA; Hammer SM
    J Infect Dis; 1998 Mar; 177(3):625-33. PubMed ID: 9498441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.